Health
Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA
HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...
2022-07-25 18:47
1967
Fuzhou Rides on the Opportunity of "Digital China" to Make Its Name in the World
FUZHOU, China, July 25, 2022 /PRNewswire/ -- "Discover Fuzhou: The Digital China Summit", the themed promo film ofFuzhou City, Fujian Province, was shown on "China screen" at Times Square, New York on July 22. Riding on the opportunity of "Digital China",Fuzhou, a coastal city, is presenting its ...
2022-07-25 15:21
2141
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
2022-07-25 11:55
2762
4DMedical Lauds U.S. House of Representatives for Including Burn Pit Population Surveillance in FY 2023 Appropriations
Thousands of Impacted Veterans Will Benefit from Congressional Efforts LOS ANGELES, July 23, 2022 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, today praised the U.S. House of Representatives for including language calling on the Departme...
2022-07-23 00:59
4764
Nisun International Cooperates with Pinhutang Distillery to Facilitate Agricultural Product Purchases
SHANGHAI, July 22, 2022 /PRNewswire/ -- Nisun International Enterprise Development Group Co., Ltd ("Nisun" or the "Company") (Nasdaq: NISN), a provider of innovative comprehensive solutions through an integration of technology, industry, and finance, announced Fanlunke Supply Chain Management ( S...
2022-07-22 20:00
3066
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
* Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins * Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial * A$4.1 million R&D Tax Incentive Scheme refund * Cash balance on 30 June 2022 of A$34.8M MELBOURN...
2022-07-22 19:25
1636
TIANGEN to Participate in the 2022 AACC Meeting
CHICAGO, July 21, 2022 /PRNewswire/ -- TIANGEN, a leading brand in the field of nucleic acid purification inChina, has announced its participation in the 2022 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo fromJuly 26 to 28 in Chicago where it wil...
2022-07-22 10:15
1887
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...
2022-07-22 07:59
2241
uLab™ clear aligner platform is now available in Australia and New Zealand
MEMPHIS, Tenn., July 22, 2022 /PRNewswire/ -- uLab Systems™, the creator of the uSmile™ clear aligner system and the uDesign® treatment planning software, announces the clearance of the uLab product suite from the Therapeutic Goods Administration (TGA) and Medsafe, the regulatory authorities for ...
2022-07-22 05:04
2242
AI-based Cancer Solution Pioneer Lunit Makes Market Debut
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer solutions, announced today that it made its stock market debut on the South Korean KOSDAQ under the ticker "A32813". Lunit's initial public offering of 1,215,800 shares of its common stock was priced a...
2022-07-21 21:00
1643
Waterdrop Launches Industry's First Customized Critical Illness Insurance Product with Waiver on Health Declarations
BEIJING, July 21, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it has partnered with China United Property Insurance Company Lim...
2022-07-21 18:00
2762
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjec...
2022-07-21 08:00
1604
Recruitment complete for Clarity's PROPELLER prostate cancer diagnostic trial
SYDNEY, July 20, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnosti...
2022-07-20 21:06
1374
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 * First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach$6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean p...
2022-07-20 21:00
1460
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01...
2022-07-20 00:15
1942
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...
2022-07-19 20:00
1557
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...
2022-07-18 20:00
1535
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data fro...
2022-07-18 20:00
1774
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China, July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onJuly 15, 2022, the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the...
2022-07-18 20:00
1656
Samsung Biologics to purchase land for its second Bio Campus
* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...
2022-07-18 19:00
1591
Week's Top Stories
Most Reposted
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 311 media titles]
2024-11-12 09:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 288 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 285 media titles]
2024-11-12 11:00
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
13462
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10126
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7487
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6205
